The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Watson Pharmaceuticals met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP earnings per share grew significantly.
Gross margins dropped, operating margins expanded, and net margins improved.
Watson Pharmaceuticals recorded revenue of $1.54 billion. The 17 analysts polled by S&P Capital IQ expected to see a top line of $1.54 billion on the same basis. GAAP reported sales were 62% higher than the prior-year quarter's $952.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $1.77. The 21 earnings estimates compiled by S&P Capital IQ forecast $1.75 per share on the same basis. GAAP EPS of $0.75 for Q4 were 436% higher than the prior-year quarter's $0.14 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 42.2%, 380 basis points worse than the prior-year quarter. Operating margin was 14.3%, 550 basis points better than the prior-year quarter. Net margin was 6.1%, 420 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $1.45 billion. On the bottom line, the average EPS estimate is $1.57.
Next year's average estimate for revenue is $5.38 billion. The average EPS estimate is $5.59.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 177 members out of 199 rating the stock outperform, and 22 members rating it underperform. Among 79 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 74 give Watson Pharmaceuticals a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Watson Pharmaceuticals is outperform, with an average price target of $76.11.
The drug and health-care investing landscape is littered with also-rans and a few major winners. Is Watson Pharmaceuticals the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Watson Pharmaceuticals to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.